STOCK TITAN

IGM Biosciences to Present at Three Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

IGM Biosciences (Nasdaq: IGMS), a clinical-stage biotechnology company focused on engineered IgM antibodies, has announced its participation in three major investor conferences in November 2024. The company will present at the Guggenheim Healthcare Innovation Conference in Boston (Nov. 11), the Stifel Healthcare Conference in New York (Nov. 19), and the Jefferies London Healthcare Conference in London (Nov. 21).

Live webcasts of all presentations will be accessible through the company's investor relations website, with recordings available for 90 days post-presentation.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

-3.27% News Effect

On the day this news was published, IGMS declined 3.27%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences:

  • Guggenheim Healthcare Innovation Conference on Monday, November 11 at 11:30 a.m. EST in Boston
  • Stifel Healthcare Conference on Tuesday, November 19 at 12:40 p.m. EST in New York
  • Jefferies London Healthcare Conference on Thursday, November 21 at 8:00 a.m. GMT/ 3:00 a.m. EST in London

A live webcast of the events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcasts will be archived on the Company’s website for 90 days following the presentations.

About IGM Biosciences, Inc.
IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. IGM’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against immunology and inflammation targets. For more information, please visit www.igmbio.com.

Contact:
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com


FAQ

What investor conferences will IGM Biosciences (IGMS) attend in November 2024?

IGM Biosciences will present at three conferences: Guggenheim Healthcare Innovation Conference in Boston (Nov. 11), Stifel Healthcare Conference in New York (Nov. 19), and Jefferies London Healthcare Conference in London (Nov. 21).

Where can I watch IGM Biosciences (IGMS) investor conference presentations?

The presentations can be viewed via live webcast on IGM Biosciences' investor relations website at investor.igmbio.com/news-and-events/events-and-presentations, with recordings available for 90 days afterward.

What time is IGM Biosciences' (IGMS) presentation at the Jefferies London Healthcare Conference?

IGM Biosciences will present at the Jefferies London Healthcare Conference on November 21, 2024, at 8:00 a.m. GMT (3:00 a.m. EST).
Igm Biosciences, Inc.

NASDAQ:IGMS

IGMS Rankings

IGMS Latest News

IGMS Latest SEC Filings

IGMS Stock Data

76.57M
23.58M
35.39%
46.88%
0.75%
Biotechnology
Pharmaceutical Preparations
Link
United States
MOUNTAIN VIEW